FoundationOne® is a fully informative Comprehensive Genomic Profile from Foundation Medicine, Inc. that complements traditional cancer treatment decision tools. FoundationOne® often expands treatment options by matching patients with targeted therapies and clinical trials that are relevant to the molecular changes in their tumor based on the most recent scientific and medical published evidence. Results are provided in a user-friendly interpretive report. FoundationOne® utilizes proprietary next-generation sequencing techniques to identify all classes of alterations in genes known to be somatically altered in solid tumor cancers.
Roche is collaborating with Foundation Medicine, Inc. to commercialize FoundationOne® in countries outside of the United States.